Anumana ECG-AI LEF (Low Ejection Fraction)
Save to shortlistLast reviewed Nov 11, 2026 against the sources listed on this page · How we review
At a glance
Anumana ECG-AI LEF is an FDA 510(k)-cleared software-as-a-medical-device that applies a deep learning algorithm to a standard 12-lead ECG to screen for low left ventricular ejection fraction (LVEF…
- FDA:
- 510(k) K250652
- Epic:
- Not on record
- Named users:
- 2 reported by the maker
- Published study:
- Yes, linked below
Description
Anumana ECG-AI LEF is an FDA 510(k)-cleared software-as-a-medical-device that applies a deep learning algorithm to a standard 12-lead ECG to screen for low left ventricular ejection fraction (LVEF <= 40%), a key indicator of heart failure. Developed with Mayo Clinic and trained on over 100,000 ECG-echocardiogram pairs, it achieved an AUROC of 0.92 (84.5% sensitivity, 83.6% specificity) in multisite validation. In the pragmatic EAGLE randomized trial it improved diagnosis of low EF by ~31% without increasing overall echocardiography use. Anumana has since added FDA-cleared 12-lead ECG algorithms for pulmonary hypertension (K252360, March 2026) and cardiac amyloidosis (K253801, April 2026).
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is Anumana ECG-AI LEF (Low Ejection Fraction) FDA cleared?
- The public FDA database has one record that our team matched to Anumana ECG-AI LEF (Low Ejection Fraction). The most recent is 510(k) K250652 (ECG-AI Low Ejection Fraction (LEF) 12-Lead algorithm (1010)), decided Jul 2025. Check that the cleared use matches how you plan to use it.FDA record K250652
- Is there published research on Anumana ECG-AI LEF (Low Ejection Fraction)?
- Yes, this listing links a study (prospective / randomized study). Check whether the patients and setting in the study look like yours.Read the study
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Prospective / randomized study
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
2 organizationsOrganizations named in public announcements or by the developer. Inclusion is not an endorsement.
Reported by the developer
Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.
Get weekly updates for Cardiology
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
Website Research PaperFDA database records
- K250652 · 510(k) · Jul 2025ECG-AI Low Ejection Fraction (LEF) 12-Lead algorithm (1010)
Matched by our team from the public FDA database; checked Nov 10, 2026.
History (2)Show
Dated events on this listing's public record, newest first.
- Sep 13, 2026
Added to CIFoundry
- Jul 28, 2025
FDA 510(k) K250652 decision datesource
Developer
Anumana, Inc. (in partnership with Mayo Clinic)
Anumana, Inc. (nference / Mayo Clinic)
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →